文献速递前列腺增生与排尿功能障碍

AdVance XP®男性吊带36个月数据:一项前瞻性多中心研究结果

36-month data for the AdVance XP® male sling: results of a prospective multicentre study.
PubMed 文献 · BJU Int · 2016-12-02

这项前瞻性多中心研究纳入115例根治性前列腺切除术后男性压力性尿失禁患者,评估AdVance XP®吊带的疗效与安全性。36个月随访时66.0%治愈、23.4%改善,24小时尿垫试验平均尿量降至21.8 g,生活质量显著改善,无术中及长期并发症。

要点

  • 36个月随访时66.0%治愈、23.4%改善,平均尿量降至21.8 g(P < 0.001)。
  • 36个月时IQOL与ICIQ-UI SF均显著改善(均P < 0.001),IIEF-5与IPSS无显著变化。
  • 无术中及长期并发症,无侵蚀或取出。

核心结论

  • AdVance XP在长达36个月的中期随访中显示出良好且稳定的疗效和低并发症率。

研究设计与样本

  • 前瞻性多中心研究,共纳入115例根治性前列腺切除术后男性压力性尿失禁患者。
  • 排除夜间尿失禁、既往尿失禁手术史、既往放疗及术前复位试验中协同区<1 cm的患者。
  • 术后评估包括标准化24小时尿垫试验、IQOL、ICIQ-UI SF、VAS疼痛评分、IIEF-5、IPSS和PGI-I。
  • 24小时尿垫试验0-5 g定义为治愈,尿量减少>50%定义为改善,其余为失败。
  • 采用Wilcoxon检验进行显著性分析。

主要发现

  • 术前24小时尿垫试验平均(中位)尿量为272.0(272.0)g。
  • 3个月随访(114例)时64.9%治愈、31.6%改善,平均尿量显著降至34.9 g(P < 0.001),平均VAS 0.5,平均PGI-I 1.5。
  • 24个月随访(80例)时68.8%治愈、22.5%改善,平均尿量显著降至19.1 g(P < 0.001),平均VAS 0.3,平均PGI-I 1.5。
  • 36个月随访(47例)时66.0%治愈、23.4%改善,平均尿量显著降至21.8 g(P < 0.001),平均VAS 0.0,平均PGI-I 1.6。
  • 36个月时平均IQOL和ICIQ-UI SF显著改善(均P < 0.001),IIEF-5和IPSS无显著术后变化,无术中及长期并发症,无侵蚀或取出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of the AdVance XP® sling (Boston Scientific, formerly American Medical Systems) in male stress urinary incontinence (SUI) after radical prostatectomy in a prospective multicentre study, as in recent years several studies have shown the effectiveness and safety of the AdVance sling for treating male SUI and in 2010 the second-generation AdVance XP was introduced with several changes in the sling design and a new needle shape. PATIENTS AND METHODS: In all, 115 patients were included. Patients with nocturnal UI, previous UI surgery, previous radiotherapy and a coaptive zone of <1 cm in the preoperative repositioning test were excluded. Postoperatively, a standardised 24-h pad test, quality-of-life scores [International Quality of Life score (IQOL) and International Consultation on Incontinence Questionnaire short form (ICIQ-UI SF)], visual analogue scale (VAS) for pain, five-item version of the International Index of Erectile Function (IIEF-5), International Prostate Symptom Score (IPSS) and Patient Global Impression of Improvement (PGI-I) score, were performed. All patients with a 0-5 g pad test were defined as cured and improved with a reduction of urine loss of >50%. All others were classified as failures. Significance analysis was performed using the Wilcoxon test. RESULTS: The mean (median) preoperative urine loss in the 24-h pad test was 272.0 (272.0) g. After a follow-up of 3 months (114 patients), 64.9% of the patients were cured and 31.6% had an improved continence status. The mean urine loss decreased significantly to 34.9 g (P < 0.001), with a mean VAS score of 0.5, and mean PGI-I of 1.5. After a follow-up of 24 months (80 patients), 68.8% of the patients were cured and 22.5% had improved. The mean urine loss decreased significantly to 19.1 g (P < 0.001), with a mean VAS score of 0.3, and mean PGI-I of 1.5. After a follow-up of 36 months (47 patients), 66.0% of the patients were cured and 23.4% had improved. The mean urine loss decreased significantly to 21.8 g (P < 0.001), with a mean VAS score of 0.0, and mean PGI-I of 1.6. The mean IQOL and ICIQ-UI SF improved significantly (both P < 0.001) after 36 months. There were no significant postoperative changes in IIEF-5 and IPSS. No intraoperative and no long-term complications occurred. No erosion or explanations occurred. CONCLUSION: The AdVance XP shows good and stable effectiveness and low complication rates even at a mid-term follow-up of up to 36 months.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bauer RM, Grabbert MT, Klehr B, et al. 36-month data for the AdVance XP® male sling: results of a prospective multicentre study. BJU Int. 2016. PMID: 27862836. doi:10.1111/bju.13704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。